2019-11-12T14:59:17-06:00 2018-12-31 521853933 JONES MARESCA & MCQUADE PA 10500 LITTLE PATUXENT PARKWAY SUITE 770 COLUMBIA MD 21044 990 2018-01-01 412161648 SOCIETY OF INTERVENTIONAL ONCOLOGY INC SOCI 2023671164 2025 M STREET NW NO 800 WASHINGTON DC 20036 CAMERON CURTIS EXECUTIVE DIRECTOR 2023671164 2019-11-11 1 LISA CHEIFETZ P01444196 4108840220 64.88.174.3 2019-11-11 13:48:28 ES P 8AD8952D00DDA1E2252D2358A354148220B4FFD3 25472CDEC520E8445491B9581FEBCD7C9E65366B 2018 2020-03-31 21:24:44Z CAMERON CURTIS 2025 M STREET NW NO 800 WASHINGTON DC 20036 1837751 0 X WWW.SIO-CENTRAL.ORG X 2005 MA TO ESTABLISH, NURTURE, AND SUPPORT INTERVENTIONAL ONCOLOGY AS THE FOURTH PILLAR OF CANCER THERAPY. 9 9 0 9 0 0 984600 454982 1274544 1381522 192 1247 0 0 2259336 1837751 434910 858500 0 0 0 0 0 0 0 1052292 1278931 1487202 2137431 772134 -299680 1175696 1185493 277178 586655 898518 598838 TO ADVANCE INTERVENTIONAL ONCOLOGY AS THE FOURTH PILLAR OF CANCER THERAPY ALONGSIDE MEDICAL, SURGICAL, AND RADIATION ONCOLOGY WORLDWIDE. 0 0 ANNUAL MEETING - SIO HOLDS AN ANNUAL MULTIDISCIPLINARY SCIENTIFIC MEETING, WITH EXHIBITS ON INTERVENTIONAL ONCOLOGY ISSUES. THE MEETING PRESENTS CURRENT INFORMATION ON RESEARCH, NEW PRODUCTS, AND NEW TECHNIQUES IN THE INTERVENTIONAL ONCOLOGY FIELD. 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 33 0 1 0 0 0 0 0 1 1 0 0 0 X 9 9 0 1 0 0 1 1 0 1 1 0 0 1 1 0 0 1 1 0 0 0 X SMITHBUCKLIN CORPORATION 2023671164 2025 M STREET NW NO 800 WASHINGTON DC 20036 X STEPHEN SOLOMON MD CHAIR 2.00 X X 0 0 0 RIAD SALEM MD MBA TREASURER 2.00 X X 0 0 0 WILLIAM RILLING MD PRESIDENT-ELECT 2.00 X X 0 0 0 UEI PUA MBBS BOARD MEMBER 1.00 X 0 0 0 ALBAN DENYS MD BOARD MEMBER UNTIL MARCH 2018 1.00 X 0 0 0 NAHUM GOLDBERG MD BOARD MEMBER 1.00 X 0 0 0 ALEXIS KELEKIS MD BOARD MEMBER 1.00 X 0 0 0 KEVIN KIM MD BOARD MEMBER 1.00 X 0 0 0 CONSTANTINOS T SOFOCLEOUS MD PHD., BOARD MEMBER 1.00 X 0 0 0 MATTHEW CALLSTROM MD PHD BOARD MEMBER 1.00 X 0 0 0 CAMERON CURTIS EXECUTIVE DIRECTOR 20.00 X 0 0 0 0 0 0 0 0 0 0 SMITHBUCKLIN CORPORATION 2025 M STREET NW STE 800 WASHINGTON DC 20036 MANAGEMENT (INCL. ED COMP.) 509631 1 454982 454982 ANNUAL MEETING 900099 1046712 1046712 ONLINE LEARNING 900099 186738 186738 MEMBERSHIP DUES 900099 116575 116575 PUBLICATIONS 900099 18997 18997 CORPORATE PARTNER PROG 900099 9500 9500 3000 3000 1381522 1247 1247 1837751 1381522 0 1247 818000 40500 502982 11464 175808 16181 28022 8365 51609 462041 2273 LICENSES AND FEES 16668 MISCELLANEOUS 3518 2137431 517245 248020 200192 330392 400000 455856 38240 58259 112985 1175696 1185493 24045 34975 200000 539000 53133 12680 277178 586655 X 418782 518328 479736 80510 898518 598838 1175696 1185493 -299680 0 X X 0 1 X 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 1837751 0 1837751 0 1837751 2137431 0 2137431 0 2137431 PART X, LINE 2: SIO BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN, AND AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS OR THAT WOULD HAVE AN EFFECT ON ITS TAX-EXEMPT STATUS. THERE ARE NO UNRECOGNIZED TAX BENEFITS OR LIABILITIES THAT NEED TO BE RECORDED. 1 UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER PO BOX 4266 HOUSTON TX 772104266 501(C)(3) 185000 IDENTIFY PROTEOMIC BIOMARKERS FOR OUTCOME PREDICTION OF LIPIODOL TACE TREATMENT AND FOR STRATEGIES TO MODULATE LIVER TUMOR IMMUNE MICROENVIRONMENT AFTER CATHETER-BASED DRUG DELIVERY. MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK NY 10065 131924236 501(C)(3) 100000 T-CELL CLONALITY AND CANCER NEOANTIGEN PRESENTATION FOLLOWING INTERVENTIONAL ONCOLOGY THERAPIES UNIVERSITY OF PENNSYLVANIA 110 MARYLAND AVE NE 509 WASHINGTON DC 20002 231352685 501(C)(3) 200000 TARGETING THE METABOLIC STRESS RESPONSE IN HEPATOCELLULAR CARCINOMA AND CHARACTERIZATION OF THE IMMUNOBIOLOGIC RESPONSE FOLLOWING TRANSARTERIAL CHEMOEMBOLIZATION OF HCC. OCHSNER CLINIC PO BOX 54965 NEW ORLEANS LA 701544965 720502505 501(C)(3) 89000 TUMOR-INDUCED TOLERANCE DRIVING EMBOLIZATION RESISTANCE AND WAITLIST FOR TRANSPLANT OUTCOMES. REGENTS OF THE UNIVERSITY OF CALIFORNIA-SAN DIEGO 9500 GILLMAN DR LA JOLLA CA 920930009 956006144 501(C)(3) 80000 EFFECTS OF CYROABLATION ON HEPATOCELLULAR CARCINOMA CANCER STEM CELLS AND THE IMMUNE RESPONSE. NORTHWESTERN UNIVERSITY 750 N LAKESHORE DR CHICAGO IL 606114579 362167817 501(C)(3) 64000 Y90 RADIOEMBOLIZATION COMBINED WITH IMMUNE CHECKPOINT BLOCKADE IN AN ANIMAL MODEL OF HEPATOCELLULAR. YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) 100000 MOLECULAR IMAGING OF THE TUMOR MICROENVIRONMENT AND IMMUNE RESPONSE IN TACE. 7 TRAVEL SCHOLARSHIPS TO THE WCIO CONFERENCE 48 40500 PART I, LINE 2: SIO AND THE WCIO CONFERENCE INVESTS IN THE SUCCESS OF THE INTERVENTIONAL ONCOLOGY (IO) FIELD BY OFFERING FUTURE IO PROFESSIONALS THE OPPORTUNITY TO ATTEND AND ENGAGE IN WCIO ANNUAL CONFERENCES THROUGH THE WCIO ANNUAL MEETING SCHOLARSHIP. THE SCHOLARSHIP IS OPEN TO ALL INTERVENTIONAL RADIOLOGY FELLOWS, DIAGNOSTIC RADIOLOGY RESIDENTS AND POST-GRADUATE MEDICAL STUDENTS WITHIN THE UNITED STATES. AN APPLICANT MUST BE IN THEIR ACGME INTERVENTIONAL RADIOLOGY FELLOWSHIP OR ACGME DIAGNOSTIC RADIOLOGY RESIDENCY AT THE TIME OF APPLICATION, OR BE A POST-GRADUATE MEDICAL STUDENT WITHIN THE IO FIELD. MINIMAL MONITORING IS REQUIRED. GRANT MONITORING: AN INTERIM PROGRESS REPORT IS REQUIRED AFTER THE FIRST SIX MONTHS OF THE PROJECT AND A FINAL REPORT NO LATER THAN 12 MONTHS AFTER THE AWARD IS SCHEDULED TO CONCLUDE. FORM 990, PART VI, SECTION A, LINE 1 THE EXECUTIVE COMMITTEE SHALL BE COMPRISED OF THE ELECTED OFFICERS OF THE ORGANIZATION, THE CHAIR, VICE-CHAIR AND PAST-CHAIR. THE COMMITTEE SHALL MEET REGULARLY AS OUTLINED IN THE BOARD POLICY. THE EXECUTIVE COMMITTEE SHALL ACT FOR THE BOARD OF DIRECTORS IN THE INTERIM BETWEEN MEETINGS OF THE BOARD BY A TWO-THIRDS VOTE. ALL DIRECTORS SHALL BE SENT ELECTRONIC NOTICE OF AN EXECUTIVE COMMITTEE VOTE WITHIN FIVE (5) BUSINESS DAYS OF SUCH VOTE, ALONG WITH THE OPPORTUNITY TO NOTIFY THE CHIEF EXECUTIVE OFFICER ELECTRONICALLY WITHIN A DATE SPECIFIED IN SUCH NOTICE (SAID DATE NOT TO BE LESS THAN FIVE (5) BUSINESS DAYS AFTER THE DATE OF SUCH NOTICE) IF THEY WISH THE EXECUTIVE COMMITTEE VOTE TO BE SUBJECT TO RATIFICATION BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 3 THE ORGANIZATION HAS ENTERED INTO A MANAGEMENT CONTRACT WITH SMITHBUCKLIN CORPORATION. UNDER THE TERMS OF THIS CONTRACT, SIO MAKES PAYMENTS TO SMITHBUCKLIN WHICH COVER STAFF SALARIES AND OTHER OVERHEAD EXPENSES. SMITHBUCKLIN'S PERFORMANCE UNDER THIS AGREEMENT IS MONITORED BY THE BOARD OF SIO. THE FEES INCURRED BY SIO DURING THE YEAR ENDED DECEMBER 31, 2018 WERE $502,982 WHICH WERE BROKEN DOWN AS FOLLOWS: EXECUTIVE MANAGEMENT $60,000, MEMBERSHIP AND OPERATIONS SERVICES - $126,141, FINANCIAL MANAGEMENT AND ACCOUNTING SERVICES - $15,000, EVENT SERVICES - $69,775, MARKETING AND COMMUNICATION SERVICES - $86,565; CREATIVE AND DESIGN SERVICES - $19,773, EDUCATION AND LEARNING SERVICES - $73,284; INFORMATION TECHNOLOGY SERVICES - $22,165; VALUE-ADDED SERVICES - $30,279. FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS MEMBERS. FORM 990, PART VI, SECTION A, LINE 7A THE ORGANIZATION'S MEMBERS ELECT THE MEMBERS OF THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE STAFF OF THE MANAGEMENT COMPANY, INCLUDING THE EXECUTIVE DIRECTOR, AND A COPY IS PROVIDED TO THE ENTIRE BOARD PRIOR TO FILING. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XII, LINE 2C: THE ORGANIZATION HAS NOT CHANGED ITS OVERSIGHT PROCESS OR SELECTION PROCESS OF AN INDEPENDENT ACCOUNTANT DURING THE TAX YEAR.